<< Go back to the Podcast page EPISODE 37: SUPPORTIVE ONCOLOGY FOR NEUROENDOCRINE CANCER Download a Transcript of this Episode >>> ABOUT THIS EPISODE What is supportive care or supportive oncology? What is cancer-related distress? How might NET patients benefit from supportive care? Yale oncologist Dr. Maryam Lustberg suggests strategies to manage cancer-related fatigue, diarrhea, nausea, mouth sores, peripheral neuropathy, distress, anxiety, and anxiety. She also addresses considerations for fertility and sexual health. MEET DR. MARYAM LUSTBERG Dr. Maryam Lustberg is an American breast oncologist. She is the Director of The Breast Center at Smilow Cancer Hospital and Chief of Breast Medical Oncology at Yale Cancer Center. Dr. Lustberg previously served as the Medical Director of Cancer Supportive Care Services at Ohio State’s Comprehensive Cancer Center. She is the Immediate Past President of the Multinational Association of Supportive Care in Cancer. She is also an Associate Editor for the Journal of Cancer Survivorship. TOP TEN QUESTIONS ABOUT SUPPORTIVE CARE: What is supportive care in cancer (or supportive oncology)? What is survivorship? How do these concepts apply to the NET community? What is the 1st step for patients to get supportive care? What are the most common treated-related adverse events or side effects? What are risk factors for them? (Will all patients experience all potential side effects?) What causes cancer-related fatigue (CRF)? What are some strategies to manage cancer-related fatigue? What are some strategies to manage diarrhea? What are some strategies to manage nausea? What are some strategies to manage mouth sores? What is peripheral neuropathy? When do patients experience it and what can be done to prevent it? What should patients understand about sexual health and fertility? How can psychosocial needs such as distress, anxiety, and depression be addressed and supported? RESOURCES READ Mitigating long-term and delayed adverse events associated with cancer treatment: implications for survivorship Survivorship Care for People Affected by Advanced or Metastatic Cancer: MASCC-ASCO Standards and Practice Recommendations Supportive Care: Low Cost, High Value Integrative Oncology Care of Symptoms of Anxiety and Depression in Adults With Cancer: Society for Integrative Oncology–ASCO Guideline LISTEN LACNETS Podcast Episode 35: "NEN Treatments: Focus on Chemotherapy" LACNETS Podcast Episode 18: Mental Health & NETs LACNETS Podcast Episode 15: Psycho-Oncology OTHER RESOURCES LACNETS Nutrition Resources LACNETS Wellness Resources including meditation & yoga DISCLAIMER LACNETS Podcasts are created for educational purposes only and do not substitute for medical advice. The views shared in this Podcast are the personal opinions of the experts and do not necessarily reflect the views of LACNETS. Please contact your medical team with questions or concerns about your individual care or treatment. THANK YOU TO OUR SPONSORS

<< Go back to the Podcast page EPISODE 20: GASTRIC NET, GASTRINOMAS & ZOLLINGER-ELLISON SYNDROME (ZES) Download a Transcript of this Episode >> ABOUT THIS EPISODE Gastroenterologist and Neuroendocrinologist Dr. David C. Metz discusses important concepts in Gastric NET, Gastrinomas and Zollinger-Ellison Syndrome, including detection, treatments, associated risks and monitoring. He also lends valuable insight on ulcers, MEN and proton pump inhibitors. MEET DR. DAVID C. METZ After earning his MD from the University of the Witwatersrand's Medical School, Dr. Metz was a resident at both the Albert Einstein Medical Center and the Johannesburg General Hospital. He went on to complete fellowships at Georgetown University Hospital as well as the National Institutes of Health. Arriving at Penn Medicine in 1993, David Metz, MD, held a variety of leadership roles within the Department of Gastroenterology, including Co-Directorship of the Neuroendocrine Tumor Center and Penn NET Treatment Program. Dr. Metz was previously a staff fellow at the National Institutes of Health, where he performed basic research in pancreatic acinar cell secretion and clinical research in Zollinger-Ellison syndrome. While at Penn Medicine, he served as Chair of the North American Neuroendocrine Tumor Society (NANETS), as a member of the Liaison Committee for Recertification of the American Board of Internal Medicine (American Gastroenterological Association representative), and on the Food and Drug Administration Gastrointestinal Drugs Advisory Committee, among other positions. Dr. Metz's clinical interests at Penn included Zollinger-Ellison syndrome and other acid-peptic conditions, Helicobacter pylori infection, non-steroidal anti-inflammatory drug gastropathy and the diagnosis and management of patients with functional and non-functional neuroendocrine tumors of the pancreas and alimentary tract. An investigator for a series of prominent clinical trials in all of these areas, Dr. Metz has published more than 200 articles on topics of clinical interest and research. He retired in July 2021 after 28 years at Penn Medicine. In 2021 Dr. Metz received the NANETS Lifetime Achievement Award that honors an individual who, over the course of their career, has provided outstanding contributions to neuroendocrine disease management through research, clinical practice or educational initiatives, as well as exceptional leadership in NANETS and dedication to its mission. TOP 10 QUESTIONS 1. What is Gastric NET? How is it found? What are the symptoms? How does it differ from “stomach cancer” or other types of NETs? 2. How is Gastric NET treated and how is it monitored? 3. What is a Gastrinoma? How and where is it found? Are Gastrinomas and Gastric NET the same thing? 4. How is a Gastrinoma treated? 5. How is a Gastrinoma monitored? How often do you recommend Endoscopies or Gastrin level lab testing? Does a high Gastrin level mean someone has a Gastrinoma or are there other causes? Can you have a high Gastrin level without having a gastrinoma? 6. What is Zollinger-Ellison Syndrome? How is it found? What are the common symptoms from ZES/functioning Gastrinomas? 7. How is Zollinger-Ellison Syndrome treated? How is Zollinger-Ellison Syndrome monitored? Does ZES put you at risk for other conditions/complications? 8. What is a common Proton Pump Inhibitor dose for someone with ZES? Is there a danger in taking PPIs for a long time or in high doses? 9. I’ve been told I have an ulcer? Am I at risk for cancer? 10. What are advances for gastric nets, gastrinomas or Z-E syndrome that we should be aware of or excited about? *Bonus question: What last words of hope would you like to leave the NET community with? RESOURCES https://www.youtube.com/watch?v=dVY3Ws3qm0s Patient Story: Zollinger-Ellison Syndrome and Gastrinoma Shaunie shares her experience living with Zollinger-Ellison syndrome and a functioning gastrinoma of the pancreas. READ Consensus Guidelines for the Management and Treatment of Neuroendocrine Tumors The North American Neuroendocrine Tumor Society Consensus Paper on the Surgical Management of Pancreatic Neuroendocrine Tumors The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Pancreatic Neuroendocrine Tumors Diagnosis of Zollinger-Ellison syndrome in the era of PPIs, faulty gastrin assays, sensitive imaging and limited access to acid secretory testing Diagnosis of the Zollinger–Ellison Syndrome Gastric Neuroendocrine Tumors (Carcinoids) Neuroendocrine Tumors: Reappraisal of Type in Predicting Outcome DISCLAIMER LACNETS Podcasts are created for educational purposes only and do not substitute for medical advice. The views shared in this Podcast are the personal opinions of the experts and do not necessarily reflect the views of LACNETS. Please contact your medical team with questions or concerns about your individual care or treatment. THANK YOU TO OUR SPONSORS

ALPHAMEDIX: Alpha PRRT with Pb-212 DOTAMTATE in NETs << Back ALPHAMEDIX - Targeted Alpha-emitter Therapy of PRRT Naive Neuroendocrine Tumor Patients CLINICALTRIALS.GOV IDENTIFIER: NCT05153772 DRUG/TREATMENT: AlphaMedix 212Pb-DOTAMTATE PHASE: 2 STATUS: Recruiting SPONSOR: Radiomedix, Inc. COLLABORATOR: Orano Med LLC https://www.youtube.com/watch?v=HECT9t4V0Ho Dr. Ebrahim Delpassand Discusses the AlphaMedix Trial (May 9, 2023) https://www.youtube.com/watch?v=3sDMIlPbepY Dr. Heloisa Soares Discusses the AlphaMedix Trial (March 10, 2023) UPDATE October 8, 2025: Press Release: AlphaMedixTM (212Pb-DOTAMTATE) achieved all primary efficacy endpoints in phase 2 study, demonstrating clinically meaningful benefits in patients with gastroenteropancreatic neuroendocrine tumors Sanofi reported that its experimental drug AlphaMedix™ (²¹²Pb-DOTAMTATE) met all its main goals in a phase 2 clinical trial, showing real benefits in people with certain gastro-pancreatic neuroendocrine tumors, whether or not they have had prior radiation treatment. The drug was generally well tolerated, and these results will inform future talks with regulators as Sanofi works toward potential approval. Read the full press release >>> DESCRIPTION: Radiomedix is sponsoring a multicenter Phase 2 study of 212Pb-DOTAMTATE enrolling adult subjects with positive somatostatin positive neuroendocrine tumors with no prior history of peptide receptor radionuclide therapy (PRRT naive). In this open-label, multicenter, single-arm Phase 2 study, adult subjects with histologically confirmed NETs and positive somatostatin analog imaging, with no prior PRRT (PRRT naive) will be enrolled to receive 212Pb-DOTAMTATE. For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here. CONTACT: Susan Cork EMAIL: scork@exceldiagnostics.com PHONE: 713-341-3203

<< Go back to the Podcast page EPISODE 9: PRRT (PART II) Download a Transcript of this Episode >> Listen to Episode 8: PRRT (Part One) with Administrative Nurse Lindy Gardner of UCLA Health >> Listen to Episode 10: PRRT (Part Three) with Josh Mailman >> ABOUT THIS EPISODE Who is eligible for PRRT? What are the side effects? Should somatostatin analogues be continued? Can PRRT be repeated when there is disease progression? NET expert and Nuclear Medicine Physician Dr. Martin Auerbach of UCLA Health answers 10 common questions about the decision-making process of PRRT. Dr. Auerbach addresses how to manage side effects, carcinoid crisis, labs, and post-PRRT imaging. MEET DR. MARTIN AUERBACH Dr. Auerbach is the Director of Nuclear Medicine at the Westwood and Santa Monica UCLA Hospitals, and Associate Professor in Nuclear Medicine, Division of Pharmacology, at the David Geffen School of Medicine at UCLA. Apart from serving as attending physician in Nuclear Medicine at the UCLA Santa Monica and Westwood Hospital, active research includes clinical studies investigating the role of molecular imaging with PET/CT to gain insights into malignant disease processes, and monitoring of cancer treatment. TOP 10 PRRT QUESTIONS 1. Who is eligible for PRRT? When considering PRRT, is there a minimum or maximum tumor size? What is the effect if a patient receives half the planned dose or a delay in receiving a dose due to low counts? 2. How do you decide on doses of radioactive agents in PRRT? Do they consider the individual’s weight or does everyone get the same dose? 3. What are the side effects of PRRT and how are they managed? 4. Do you continue SSA with PRRT and if so when should one receive it? 5. Can people have carcinoid crisis with PRRT? If so, how is this treated? 6. When or how often are labs done? Which labs and what are you looking for? 7. When do you do imaging? Which imaging to you do? 8. When would you expect to see a response with PRRT and what is the statistics about the shrinkage or response that is expected? 9. For those who have received 4 doses of Luthatera, what happens if/when there is progression, can PRRT be repeated? Can people have more than 4 doses of Lutathera? 10. What is the difference between alpha and beta PRRT? How would you decide between the alpha or beta PRRT? ADDITIONAL RESOURCES Read the LACNETS Blog Post "These Four Letters: PRRT" >> Click here for additional PRRT Resources >> DISCLAIMER LACNETS Podcasts are created for educational purposes only and do not substitute for medical advice. The views shared in this Podcast are the personal opinions of the experts and do not necessarily reflect the views of LACNETS. Please contact your medical team with questions or concerns about your individual care or treatment. THANK YOU TO OUR SPONSORS

Join NCF for Mar2025. Explore event details, dates, times, and discover opportunities to connect, learn, and get involved. < Back to the upcoming events page https://www.youtube.com/watch?v=Ton887q1R6s Download the Transcript Here >>> Download the Presentation Slides Here >>> ABOUT Learn about PRRT from UCLA's Lead PRRT Nurse Linda Gardner. She addresses common questions about what to expect before, during, and after the treatment, as well as concerns about radiation safety. ABOUT LINDA GARDNER, MSN, RN, VA-BC LINDA (LINDY) GARDNER, MSN, RN, VA-BC Lead Nurse, Nuclear Medicine UCLA Health Lindy has over two decades of Interventional Radiology experience prior to transitioning over to Nuclear Medicine in March of 2017. She obtained her RN qualification in 1993 from John Moores University of Liverpool, (LJMU) United Kingdom, she is a graduate from the University Of Dundee, Scotland where she received her Bachelors, and Master’s of Science in Nursing. In her Nuclear Medicine role Lindy is the lead nurse for the Peptide Receptor Radionuclide Therapy (PRRT) program, from the expanded access program (EAP) through to the FDA approved commercial program. She has presented this program to a national and international audience; her skills are utilized as an expert liaison for institutions commencing the PRRT program, focusing on the patient experience, education, and therapy administration. Lindy is the nursing pillar lead for The International Center for Precision Oncology foundation (ICPO), with her focus on education, support and navigation for the NET patient journey. She is also the lead nurse for Radioligand Therapy (RLT) for prostate cancer within Theranostics at UCLA, covering both clinical application and research. Lindy is a member of the Association for Radiologic and Imaging Nursing (ARIN), and the Association for Vascular Access (AVA), holding her board certification in vascular access (VACC). She serves as a member of the Neuroendocrine Cancer Foundation Medical Advisory Committee and The Healing NET Scientific Advisory Committee. The opinions expressed by the guest presenters, as well as the questions asked by the audience, have not been created or suggested by the Neuroendocrine Cancer Foundation or the sponsors of this program. The Neuroendocrine Cancer Foundation does not endorse or promote any of the views, opinions or information provided in this presentation. Audience members should not rely solely on the opinions or information expressed by the guest presenter and should seek guidance and direction from their own medical advisors regarding any choices they make about their health or treatments. THANKS TO OUR SPONSORS

COMPOSE: PRRT with Lu-177 EDOTREOTIDE versus “Standard of Care” in Well-Differentiated Aggressive G2 & G3 GEP-NETs << Back ITM (COMPOSE) Phase III Clinical Trial: 177 LU-EDOTREOTIDE VS. Best Standard of Care in Well-Differentiated Aggressive G2 & G3 GEP-NETs CLINICALTRIALS.GOV IDENTIFIER: NCT04919226 DRUG/TREATMENT: 177Lu-Edotreotide PRRT (Peptide Receptor Radionuclide Therapy) PRRT versus CAPTEM (Capecitabine and Temozolomide), Everolimus or FOLFOX (Folinic acid + Fluorouracil + Oxaliplatin) PHASE: 3 STATUS: Recruiting SPONSOR: ITM https://www.youtube.com/watch?v=r1hmEzrooxE Dr. Heloisa Soares Discusses COMPOSE: PRRT -LU-177 EDOTREOTIDE https://www.youtube.com/watch?v=w9kA8_gmVfM Dr. Will Pegna Discusses COMPOSE: PRRT - LU-177 EDOTREOTIDE Starting at 9:04 UPDATE (March 2025) https://www.youtube.com/watch?v=H0H1RNwIwV0 The Neuroendocrine Cancer Foundation @NCFCancer (previously @LACNETS) interviews Mayo Clinic Medical Oncologist and #NetCancer expert Dr. Thor Halfdanarson at the 2025 ENETS Annual Medical and Scientific Conference in Krakow, Poland (March 5-7, 2025). Dr. Halfdanarson shares the breaking news of positive results from ITM’s phase 3 COMPETE trial, the first prospective, randomized phase 3 study comparing PRRT with an active treatment (everolimus). DESCRIPTION: ITM is sponsoring “COMPOSE,” an international phase III clinical study to evaluate the efficacy, safety and impact on quality of life of Targeted Radionuclide Therapy (PRRT) with no-carrier-added lutetium-177-edotreotide (n.c.a. 177Lu-edotreotide) compared to a standard therapy with either CAPTEM or everolimus or FOLFOX, in patients with well-differentiated advanced Grade 2 and Grade 3, somatostatin receptor-positive (SSTR+) neuroendocrine tumors of gastroenteric or pancreatic origin (G2 and G3 GEP-NETs). The study is being conducted predominantly in Europe, North America, India and Australia, in approximately 10 countries and 40 sites. For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here. CONTACT: Dr. Nicolas Schneider or Amanda Rotger at ITM EMAIL: info-solucin@itm-radiopharma.com

SORENTO™: Subcutaneous Octreotide for GEP-NETs (CAM2029) << Back SORENTO ™ - A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NETs CLINICALTRIALS.GOV IDENTIFIER: NCT05050942 DRUG/TREATMENT: CAM2029, octreotide LAR, lanreotide ATG PHASE: 3 STATUS: Recruiting SPONSOR: Camurus AB https://www.youtube.com/watch?v=9lKvu6-J4-g Dr. Simron Singh Discusses the SORENTO™ Trial DESCRIPTION: Camurus is sponsoring a phase 3 study to compare the effectiveness and safety of CAM2029 to octreotide LAR or lanreotide ATG in patients with advanced, well-differentiated GEP-NET. Patients who experience progressive disease in the randomized part of the study may proceed to an open-label extension part with intensified treatment with CAM2029. For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here. CONTACT: Camurus AB EMAIL: medicalinfo@camurus.com PHONE: +46 46 286 57 30 Principal Investigator: Simron Singh, MD, MPH Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada

Join NCF for Zeal. Explore event details, dates, times, and discover opportunities to connect, learn, and get involved. < Back to the upcoming events page REGISTER Location CinemaWest Beach Cities 4DX, ScreenX & Giant Screen with Laser831 S Nash StEl Segundo, CA 90245 Parking The open lot behind the cinema is the closest, free parking as is the structure attached to it. There is handicapped parking in both and a ramp from the first level of the structure to the theater entrance/patio. Event Schedule & Comfort Tips Saturday’s forecast in El Segundo is a high of 74°F and a low of 59°F . The Mix & Mingle portion of the event will take place outdoors on Pink’s Patio, so we recommend bringing a light layer as the evening cools, and the theater may be cooler inside. 2:30 PM - 3:30 PM – Light savory & sweet bites served on Pink's Patio outside the theater 3:45 PM – Final arrival for screening & last chance to grab your concessions 4:00 PM – Zeal for Life Introduction by Rain Bennett & Screening (90 minutes) 5:30 PM – 'Continuing the Conversation' - Q&A With Dr. Aman Chauhan, Lisa Yen, Rain Bennett, and Dusty Hurley Check-In Please check in at the Neuroendocrine Cancer Foundation registration table when you arrive and be sure to pick up your complimentary Popcorn & Soda/Water Voucher. Regrets If you're unable to make it, please email Heather Davis at Heather@NCF.net . For additional questions, please contact Heather@NCF.net . We look forward to sharing this meaningful afternoon with you. ABOUT Join the Neuroendocrine Cancer Foundation on Saturday afternoon, March 7th, for a special screening of Zeal for Life . To see firsthand what makes those living with neuroendocrine cancer, the experts who treat them, and their caregivers - zealous. Optimism, determination, and wholehearted dedication collectively contribute to longevity and living with zeal! Coping and navigating a cancer diagnosis can be daunting and fraught with overwhelm and misunderstanding, but in this film we take a moment to appreciate when gaps are bridged and connections made to exponentially affect change. This documentary focuses on how patients & caregivers, medical experts and patient advocacy organizations work collectively to better navigate and manage neuroendocrine cancer. The Carcinoid Cancer Foundation recognized this need nearly 60 years ago. For decades, CCF has connected patients with physicians who know and appreciate neuroendocrine tumors. They made evidence-based education accessible to physicians and patients alike. Through many avenues and efforts, CCF has driven awareness, study and understanding of this uncommon disease. This poignant and illuminating film delves into the lives of individuals and families navigating the insidious realm of Neuroendocrine Cancer, or Neuroendocrine Tumor (NET)—an uncommon and notoriously complex treatment, often misdiagnosed or diagnosed after metastasis. Through intimate interviews and compelling spotlight the extraordinary resilience of NET patients, caregivers and the experts who care for them is captured. THANKS TO OUR SPONSORS T he opinions expressed by the guest presenters, as well as the questions asked by the audience, have not been created or suggested by the Neuroendocrine Cancer Foundation or the sponsors of this program. The Neuroendocrine Cancer Foundation does not endorse or promote any of the views, opinions or information provided in this presentation. Audience members should not rely on the opinions or information expressed by the guest presenter and should seek guidance and direction from their own medical advisors regarding any choices they make about their health or treatments.

<< Go back to the Podcast page EPISODE 25: WHAT TO KNOW ABOUT GRADE 3 POORLY DIFFERENTIATED NEUROENDOCRINE CARCINOMA (NEC) Download the transcript here: Podcast Episode 25_Raj .pdf Download PDF • 201KB ABOUT THIS EPISODE What are Grade 3 Poorly Differentiated Neuroendocrine Carcinoma (NEC)? What makes NEC unique? Can a NET transform to NEC? Dr. Nitya Raj from Memorial Sloan Kettering Cancer Center in New York City explains NEC tumor biology and how it guides treatment strategy. She also discusses current clinical trials and research. MEET DR. NITYA RAJ Nitya Raj, MD is a gastrointestinal medical oncologist with a clinical practice devoted to caring for people with gastrointestinal and endocrine cancers, including neuroendocrine tumors, adrenal cancer, colorectal cancer, pancreatic cancer, and other gastrointestinal cancers. Dr. Raj’s research focuses on advancing treatments for neuroendocrine cancers (a rare group of tumors that often begin in the body’s digestive organs as well as adrenocortical cancers. Dr. Raj is also studying ways to improve our understanding of how neuroendocrine tumors change at the genetic level over time and as a result of different treatments, in order to better personalize our care for people with these cancers. Dr. Raj’s work has been recognized and supported by the American Society of Clinical Oncology with a Young Investigator Award and Career Development Award, as well as by the Neuroendocrine Tumor Research Foundation with a Pilot Award. Nationally, Dr. Raj serves on the Neuroendocrine Tumor Task Force of the National Cancer Institute. Dr. Raj is on the faculty of Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College. TOP 10 QUESTIONS What is a poorly differentiated grade 3 neuroendocrine carcinoma (NEC)? Are all NEC poorly differentiated and are all poorly differentiated NEC? Where are they located? How are NEC found? How does one know it is a NEC? How is NEC unique compared to other types of neuroendocrine cancers? In particular, how is it different from grade 3 NET? What types of labs, scans, or testing for NEC? Can a NEC be surgically removed? How would you decide if, when, and how? How are NEC treated medically (or nonsurgically)? What treatment might you use as second-line? What is the role of liver-directed therapy? What is the role of immunotherapy? What are clinical trials we should be aware of or exciting new treatments in the pipeline for NEC? How are NEC monitored? What types of bloodwork or tests should be done and how often should they be done? What words of hope would you like to leave the neuroendocrine cancer community with? RESOURCES Click here for more resources for high-grade >> READ Expert Consensus Practice Recommendations of the North American Neuroendocrine Tumor Society for the management of high grade gastroenteropancreatic and gynecologic neuroendocrine neoplasms in: Endocrine-Related Cancer Volume 30 Issue 8 (2023) CLINICAL TRIAL SWOG 2012 Trial DISCLAIMER LACNETS Podcasts are created for educational purposes only and do not substitute for medical advice. The views shared in this Podcast are the personal opinions of the experts and do not necessarily reflect the views of LACNETS. Please contact your medical team with questions or concerns about your individual care or treatment. THANK YOU TO OUR SPONSORS

<< Go back to the Podcast page EPISODE 21: WHAT TO KNOW ABOUT SMALL BOWEL NETS Download a Transcript of this Episode >> ABOUT THIS EPISODE How are small bowel NETs diagnosed, treated, and monitored? How is it different from other types of NETs? What are some exciting new treatments for small bowel NETs? NET oncologist Dr. David Zhen of Fred Hutchinson Cancer Center in Seattle answers 10 common questions about small bowel NETs. MEET DR. DAVID B. ZHEN Dr. David Zhen is a medical oncologist who specializes in treating patients with gastrointestinal cancers. His research centers around the development of clinical trials evaluating new therapies and combination approaches for the treatment of patients with gastrointestinal cancers, particularly for neuroendocrine and gastroesophageal cancers. He is also conducting research to understand the interactions of the immune system in gastrointestinal cancers and how this can be manipulated to improve upon the response to immunotherapy drugs called checkpoint inhibitors, which block a braking system that cancers use to tamp down the immune response. TOP 10 QUESTIONS 1. What are small bowel NETs? Where are they located? 2. How are small bowel NETs found? What are the symptoms of a small bowel NET? 3. What types of labs, scans, or testing is done to determine if someone has a small bowel NET? Why are small bowel NETs not found in routine endoscopy or colonoscopy? 4. What are some ways that small bowel NETs differ from other types of NETs? What makes small bowel NETs unique from other types of NETs? 5. How do you decide if the small bowel NET(s) can be surgically removed? What type of surgeon would make that determination? 6. How are small bowel NETs treated medically? 7. How are treatments sequenced? 8. How are the treatments different from other NETs? 9. What are some exciting new treatments in the pipeline for small bowel NETs? What are clinical trials we should be aware of for small bowel NETs? 10. How are small bowel NETs monitored? What types of bloodwork or tests should be done and how often should they be done? What is the best type of scan for small bowel NETs? Bonus: What words of hope would you like to share with the NET community? RESOURCES WATCH https://www.youtube.com/watch?v=sZIVip3CIxI "Systemic Therapy: GI NET" - 2020 LACNETS Patient Education Conference https://www.youtube.com/watch?v=9N9QPcoLF2s Recording of Dr. Zhen Visiting the LACNETS Support Group https://www.youtube.com/watch?v=VhWI-yBXHYw Patient Story: From Diagnosis to Patient Advocacy - 2022 LACNETS NET Patient Conference https://www.youtube.com/watch?v=aNY8oejLIKI NET Patient shares how she has learned not just to survive, but also to thrive . LISTEN Listen to the NETRF NETWise Special Episode: Small Bowel NET + Take the LACNETS Quiz READ 2017 The Surgical Management of Small Bowel Neuroendocrine Tumors: Consensus Guidelines of the North American Neuroendocrine Tumor Society 2017 The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine Tumors DISCLAIMER LACNETS Podcasts are created for educational purposes only and do not substitute for medical advice. The views shared in this Podcast are the personal opinions of the experts and do not necessarily reflect the views of LACNETS. Please contact your medical team with questions or concerns about your individual care or treatment. THANK YOU TO OUR SPONSORS

Join NCF for Sep2025. Explore event details, dates, times, and discover opportunities to connect, learn, and get involved. < Back to the upcoming events page https://www.youtube.com/watch?v=_dE7__jhf9I ABOUT The field of PRRT (Peptide Receptor Radionuclide Therapy) is evolving rapidly, and patients are hearing more about new developments like alpha therapies, the recent NETTER-2 and COMPETE trial results, and other advances. Join medical oncologist Dr. Udhayvir Singh Grewal from the Winship Cancer Institute of Emory University as he breaks down what these changes mean for people living with neuroendocrine cancer. This webinar will help patients and caregivers make sense of emerging research and therapies—and what they may mean for the future of NET treatment. Download Presentation Slides >>> ABOUT DR. UDHAYVIR SINGH GREWAL Udhayvir Singh Grewal, MD Assistant Professor of Medical Oncology Winship Cancer Institute Emory University School of Medicine Udhayvir S. Grewal, MD, is a gastrointestinal and neuroendocrine tumor (GI/NET) medical oncologist at the Winship Cancer Institute of Emory University and an Assistant Professor of Medical Oncology at the Emory University School of Medicine in Atlanta, Georgia. His research focuses on drug development and care-delivery innovations for patients with neuroendocrine tumors. Dr. Grewal serves on the North American Neuroendocrine Tumor Society (NANETS) Membership & Diversity Committee and the European Neuroendocrine Tumor Society (ENETS) Grade 3 NENs Task Force. After medical school at Government Medical College in Patiala, India, Dr. Grewal completed his internal medicine residency at LSU Health Sciences Center–Shreveport and a hematology/medical oncology fellowship at the University of Iowa Holden Comprehensive Cancer Center, where he also remains an active collaborator with the UIowa NET SPORE team. T he opinions expressed by the guest presenters, as well as the questions asked by the audience, have not been created or suggested by the Neuroendocrine Cancer Foundation or the sponsors of this program. The Neuroendocrine Cancer Foundation does not endorse or promote any of the views, opinions or information provided in this presentation. Audience members should not rely on the opinions or information expressed by the guest presenter and should seek guidance and direction from their own medical advisors regarding any choices they make about their health or treatments. THANKS TO OUR SPONSORS

<< Go back to the Podcast page EPISODE 15: PSYCHO-ONCOLOGY Download a Transcript of this Episode >> ABOUT THIS EPISODE What is psycho-oncology and how can it benefit those living with NET? Psychiatrist Dr. Mona Mojtahedzadeh of Simms/Mann UCLA Center for Integrative Oncology discusses whole-person care for cancer patients and caregivers. From “scanxiety” to sleep hygiene, she acknowledges the range of challenges of living with cancer and shares solutions to improve mental well-being and overall health. MEET DR. MONA MOJTAHEDZADEH Mona Mojtahedzadeh, MD, is a psychiatrist at Simms-Mann/UCLA Center for Integrative Oncology , which allows her to continue to perform a work of meaning within a valued population who embrace her into some of their most pivotal moments along their cancer illness trajectory. Dr. Mojtahedzadeh is board certified in Psychiatry as well as in Consultation-Liaison Psychiatry. She obtained her MD from Tehran, Iran’s Shahid Beheshti University of Medical Sciences. She was a general and family practitioner at an underserved health and urgent care clinic in Iran. She completed her psychiatry training through residencies at Texas Tech University Health and Science Center coupled with Loma Linda University Health , where she was granted the department’s research award of the year. She completed a consultation-liaison (C-L) psychiatry fellowship at the University of Southern California and Los Angeles County (LAC+USC) and later served as an Assistant Professor in the Department of Supportive Care Medicine at City of Hope National Medical Center and an Adjunct Assistant Professor of Psychiatry at USC. Her scholarly work includes over 32 publications, posters, and book chapters in areas of medicine, mental health, and their overlap. Learn more about Dr. Mojtahedzadeh and her background here. TOP 10 PSYCHO-ONCOLOGY QUESTIONS 1. Who might seek a psychiatrist? How does one go about finding a psychiatrist that is right for him or her? 2. What is psycho-oncology? If someone living with NET is looking for a psychiatrist, should they seek someone who has trained in psycho-oncology? How does one find such a person? 3. How do you determine if symptoms such as depression, anxiety, mood swing, or fatigue are symptoms caused by their NET cancer or not? 4. Is it safe for NET patients, particularly those with high levels of serotonin, to take antidepressants such as SSRIs that may increase levels of serotonin? 5. If someone living with NET struggles with depression, what is your approach? How do you determine the best treatment option? 6. If someone living with NET struggles with anxiety, how would you approach this patient and how might you manage it? 7. If someone living with NET struggles with sleep issues, what might your thoughts be? 8. What suggestions might you have for loved ones of someone living with cancer who is trying to support someone struggling with depression, anxiety, or mood swings? 9. What suggestions do you have for coping with one’s cancer diagnosis? How might one find some stability and peace during what often feels like a rollercoaster ride? 10. What last words of hope would you leave with the audience? ABOUT PSYCHO-ONCOLOGY "Psycho-oncology is a broad term which encompasses a wide range of psychosocial care to anyone impacted by cancer, whether it is for the individual patient themselves or for their families, loved ones, or caretakers. The idea is to address the breath and soul that may go along with a cancer illness journey. This would ideally incorporate a collaborative work between providers from various disciplines including psychiatrists, psychologists, social workers, oncologists, nurses, palliative care providers, spiritual leaders, nutritionists, and so on who would specialize in the care for cancer, and with a shared mission to improve the well-being and the quality of life of those impacted.” —Mona Mojtahedzadeh, MD PSYCHO-ONCOLOGY RESOURCES Books & Poems The Human Side of Cancer: Living with Hope, Coping with Uncertainty by Jimmie C. Holland, M.D. and Sheldon Lewis On Grief and Grieving: Finding the Meaning of Grief Through the Five Stages of Loss by Elisabeth Kubler-Ross, M.D. & David Kessler Kessler, D. (2019). Finding meaning: The sixth stage of grief. Simon and Schuster When Breath Becomes Air by Paul Kalanithi Man’s Search for Meaning by Viktor Frankl Review Articles Isenberg-Grzeda, E., MacGregor, M., Matsoukas, K., Chow, N., Reidy-Lagunes, D., & Alici, Y. (2020). Must antidepressants be avoided in patients with neuroendocrine tumors? Results of a systematic review. Palliative & supportive care, 18(5), 602-608. La Salvia, A., Pomeri, A. P., Persano, I., Trevisi, E., Parlagreco, E., Colombi, N., ... & Oliva, F. (2021). Serotoninergic brain dysfunction in neuroendocrine tumor patients: A scoping review. Comprehensive Psychiatry, 109, 152244 LACNETS Resources Grief Resources >> Caregiver Resources >> Caregiver, Palliative Care and Supportive Care Playlist >> Additional Resources American Psychosocial Oncology Society (APOS) Helpline: (866) 276-7443 apos-society.org Cancer Support Community Helpline: (888) 793-9355 cancersupportcommunity.org American Cancer Society Helpline: (800) 227-2345 Cancer.org DISCLAIMER LACNETS Podcasts are created for educational purposes only and do not substitute for medical advice. The views shared in this Podcast are the personal opinions of the experts and do not necessarily reflect the views of LACNETS. Please contact your medical team with questions or concerns about your individual care or treatment. THANK YOU TO OUR SPONSORS